LOXO Oncology Competitors, Revenue, Alternatives and Pricing

Claim your profile


Total Funding:$125.3M
Lead Investor(s):Morgan Stanley

Industry Ranking

State Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • LOXO Oncology's estimated annual revenue is currently $45M per year.
  • LOXO Oncology received $294.8M in venture funding in June 2017.
  • LOXO Oncology's estimated revenue per employee is $201,000
  • LOXO Oncology's total funding is $125.3M.

Employee Data

  • LOXO Oncology has 224 Employees.
  • LOXO Oncology grew their employee count by 66% last year.
  • LOXO Oncology currently has 6 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
Connecticut Pha...
The Scienomics ...
Breckenridge Ph...
Avara Pharmaceu...
Tower Laborator...
Purdue Pharma L...
TriRx Pharmaceu...
LOXO Oncology
Missing a competitor? Contribute!?

Loxo Oncology is a biopharmaceutical company dedicated to developing highly-selective medicines for patients with genomically defined cancers. Our pipeline is focused on treatments aimed at cancers caused by a single inappropriate DNA change, known as oncogenic drivers, which the tumor depends on for growth and survival. Loxo Oncology develops purpose-built medicines designed to selectively and potently inhibit these oncogenic drivers. We believe that this approach, combined with the use of tumor genomic testing to identify appropriate patients, will allow us to develop medicines that provide best-in-class disease control and safety and, ultimately, deliver on the promise of precision medicine. We are based in Stamford, CT with sites in San Francisco, CA and Boulder, CO. For more information about Loxo Oncology, please visit us at www.loxooncology.com.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







LOXO Oncology News

09/07/2019 - Inside drugmakers' strategy to boost cancer medicines with ...

Developed by Eli Lilly and Co's Loxo Oncology and marketed by ... with oncologists and pharmaceutical and diagnostic industry executives.

09/08/2019 - Biopharma Pushes for Wider Acceptance, Use and ...

One example is the drug Vitrakvi, developed by Eli Lilly and its Loxo Oncology, which is marketed by Bayer. Vitrakvi works on cancers where ...

09/04/2019 - Loxo Oncology, Inc. (LOXO) Book to Market Runs to 0.052546

The bigger the book-to-market ratio is, the more fundamentally cheap is the investigated company. Loxo Oncology, Inc. (LOXO) has a BTM ratio ...

LOXO Oncology Funding

DateAmountRoundLead InvestorsReference
2014-05-07$24.0MBNew Enterprise AssociatesArticle
2017-06-22$294.8MUndisclosedMorgan StanleyArticle

LOXO Oncology Executive Hires

2014-05-07Mikel MoyerChief Scientific OfficerArticle
2014-10-29Jennifer LowChief Medical Officer/EVP R/DArticle